Tempus AI (TEM) Stock: Gilead Partnership Deepens as Oncology Data Demand Grows

TLDR

• Tempus AI announced an expanded multi-year collaboration with Gilead Sciences (GILD) to advance Gilead’s oncology pipeline using Tempus’ AI-driven Lens platform.
• The deal gives Gilead enterprise-wide access to Tempus’ de-identified multimodal data across multiple cancer indications.
• Tempus’ Diagnostics segment grew revenues 111.5% year over year in 2025, with oncology volume up 26%.
• The Data and Applications segment posted $100.4M in Q4 2025 revenue, up 25.1% YoY, with total remaining contract value topping $1.1 billion.
• TEM stock has gained 17.9% over the past year, while the broader medical info systems industry fell 20%.

Tempus AI has struck an expanded deal with Gilead Sciences, deepening a relationship that had already been delivering real-world oncology data for Gilead’s research and development work.

The new agreement gives Gilead enterprise-wide access to Tempus’ AI-powered Lens platform. That means broader access to de-identified patient data across multiple cancer types, plus dedicated analytical services from the Tempus team.

Tempus AI, Inc., TEM

Previously, Gilead used Tempus’ data repository for specific tasks — trial design, biomarker strategy, indication selection and health outcomes analysis. This expansion takes things several steps further.

Patrick Loerch, SVP of Clinical Data Science at Gilead, called the partnership a reflection of their “shared priority of putting patients at the heart of innovation.” Ryan Fukushima, CEO of Tempus Data & Apps, said the expanded access would deliver AI-driven insights to support Gilead’s R&D work. Financial terms were not disclosed.

Diagnostics Growth Backing the Deal

The timing of this collaboration comes as Tempus reports some of its strongest diagnostic numbers yet.

In 2025, Tempus‘ Diagnostics segment posted 111.5% revenue growth year over year. Oncology testing volume rose 26%, Hereditary grew 29%, and its MRD testing category hit around 4,700 tests in Q4 alone — up 56% quarter over quarter.

Management is projecting oncology growth of around 30% in 2026, driven by rising adoption of genomic sequencing and expanding MRD reimbursement coverage.

The company is also working through regulatory pricing improvements, with the transition of its xT CDx test from a lab-developed version to the FDA-approved pathway. The average selling price in Q4 2025 was approximately $1,640, up about $40 from Q3.

Data Business Scaling Steadily

Tempus‘ Data and Applications segment has become the other main pillar of its growth story.

Q4 2025 revenues for the segment reached $100.4 million, up 25.1% year over year. Net Revenue Retention stood at 126%, indicating existing customers are spending more. The company closed 2025 with over $1.1 billion in total remaining contract value.

Management is guiding for roughly $1.59 billion in total 2026 revenues, implying around 25% growth.

Tempus is also investing in large-scale AI foundation models trained on its proprietary datasets, with plans to expand beyond oncology into radiology, cardiology and neuropsychology.

The stock is currently trading at a forward price-to-sales ratio of 5.02x, below the industry median of 5.38x.

Gilead, meanwhile, is in an active acquisition phase. The company has announced three deals totaling approximately $15 billion, including a $7.8 billion acquisition of Arcellx and a $5 billion deal for Tubulis. Analysts at TD Cowen, BMO Capital, and Truist Securities all maintain Buy or Outperform ratings on Gilead with price targets ranging from $155 to $174.

The post Tempus AI (TEM) Stock: Gilead Partnership Deepens as Oncology Data Demand Grows appeared first on CoinCentral.